Citations

Clear

32 citation(s) found for "Smith, Andrew".

Letters of reference for PGY1 pharmacy residency candidates: A survey of residency program directors and opinion statement
Dy‐Boarman, Eliza A. , McCreary, Erin K. , Nisly, Sarah A. , Paloucek, Frank P. , Peterson, David M., Smith, Andrew , Schramm, Garrett E. , Skrupky, Lee P. , Gurgle, Holly E. , Isaacs, Alex N. , McCreary, Erin K , Peterson, David M.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | April 19, 2022 | Volume: 4 | Issue: 3 | Pages: 379-389

10.1002/jac5.1370 Get It

AbstractIntroductionAlthough letters of reference (LORs) are required for postgraduate year one (PGY1) residency applications and used to distinguish between candidates, an evaluation of residency program director (RPD) perceptions and values surrounding LORs has not been described.ObjectiveThe aim of the study was to describe PGY1 RPDs' processes, values, and perceptions surrounding LORs.MethodsThis was a cross‐sectional descriptive survey. After assessing content validity, the Education and Training Practice and Research Network (PRN) taskforce sent a 25‐item electronic survey to 1266 PGY1 RPDs. Survey questions captured program demographics, LOR requirements, processes for LOR review, and perceptions about the value of LORs. Two open‐ended questions solicited suggestions for LORs and the existing standardized form; responses were evaluated via thematic analysis.ResultsA total of 291 (24%) programs completed the survey. LORs were rated as extremely or quite valuable by 82% of respondents and moderately valuable by 16% of respondents. Scoring rubrics for LOR evaluation were used by 79% of programs, and performance ratings were reported to impact interview consideration by a majority of programs. Accuracy, detailed comments, and inclusion of specific candidate strengths and areas for improvement were rated as extremely or quite important characteristics by 90% or more of respondents. Specific strengths were reported to be present in LORs more than half of the time by 81% of programs; however, accuracy, detailed comments, and inclusion of specific areas for improvement were only reported to be present about half the time or less by 41%, 63%, and 63% of respondents. Among 207 suggestions submitted to improve LOR utility, common themes included a desire for LOR authors to have candid discussions with candidates prior to letter writing, to contextualize their relationship with the candidate, and provide honest and specific assessments.ConclusionLORs remain highly valued by PGY1 RPDs during application review. Several notable findings were observed, resulting in recommendations for LOR authors, residency applicants, and the standardized LOR form.
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction
Givertz, Michael M. , Shah, Palak , McNulty, Steven E., Anstrom, Kevin J. , Mahr, Claudius , Gupta, Divya , Redfield, Margaret M. , Lala, Anuradha , Desvigne‐Nickens, Patrice , Braunwald, Eugene, Investigators, LIFE, Mohammed, Selma F. , Birru, Hellina, Aboye, Etsubdink, Lam, Phillip H. , Escobar, Nicole, Fink, Maria Cristina Domingues , Cappola, Thomas P. , Sheaffer, Wendy , Reilly, Bonitta, Ferree, J W, Ciezkowski, Gina, Herrera, Glenda, Mehta, Hirsch, Delucca, Rosemarie, Doddamani, Sanjay , Thomas, B. , Machen, Laurie, Kim, J., Christina, Athas, Lampert, Brent C. , Fontenelle, Cindy, Eiswirth, Clement, Rock, Darlene, Egnaczyk, Gregory F. , Rentas-Sherman, Enya, Barr, Deborah, Damato, Adrianna, Calayo, Christine, Herre, John M. , Carroll, Amanda , Keebler, Mary , Setliff, Bandaa, Gulati, Sanjeev , Winkler, K, Curtin, Laura, Ohmart, Carly, Halvorson, John, Mudd, James O., Camacho, S. Albert , Palardy, Maryse , Shah, Neha, Picardi, Kristina, Krishnamoorthy, Arun, Maximin, Adrienne, Horstmanshof, Douglas , Seiler, Beverly, Xu, Zi J., Mersola, S., Kransdorf, E. , Fonk, T., Oliveira, Guilherme H., Semenec, Terrence, Leo, Peter , Dunlap, Mark E. , Felker, G. Michael , Taylor, Lacey D., Sheehan, Mary, Levine, Sharon, Cocca-Spofford, Diane, Brooks, Liana, Cunningham, Thomas F., Acker, Nancy, Milbrandt, Susan, Gatzke, Janet, Dávila‐Román, Víctor G. , Bult, Karen, Weber, Elizabeth, Lesko, Mary, Mikhalkova, Deana , Fitzgerald, Kathleen, Whellan, David J. , Gutierrez, Jonathan, Goldsborough, Yavette, Caikauskaite, Indre, Skopicki, Hal A. , Huggins, Gordon S. , Yuen, Nathan, Haynes, Abbey, Katie, Carr, Snell, Gail, Smith, Andrew L. , Walker, Brandon S. , JOHNSON, J. Y. M., Henderson, Simmone, Pauwaa, Sunil, Bhat, Geetha , Gagliardi, A.R.T., Mann, Douglas L. , Vader, Justin M. , Starling, Randall C. , Margulies, Kenneth B. , Kiernan, Michael S. , Lewis, Gregory D. , DeVore, Adam D. , Hernandez, Adrian F. , Braunwald, Eugene , Investigators, LIFE, Aboye, Etsubdink A, Fink, Maria, Ferree, Jenny, Ravichandran, Ashwin Kumar , Herrera, Glenda, Kanwar, Manreet , Williams, Julie , Bhimaraj, Arvind , Lindenfeld, JoAnn , Gordon, Mary Ellen , Gulati, Sanjeev K., Winkler, Krystal, Tang, W.H. Wilson , Gorodeski, Eiran Z. , Norton, Nadine , Nichols, Julie, Taylor, Lacey, Cunningham, Thomas, Dirks, Anne, Wever‐Pinzon, Omar , Gilotra, Nisha A , Walker, Brandon, Henderson, Simmone, Gagliardi, Ann, Shah, Palak

Mayo Clinic

JAMA Cardiology | November 3, 2021 | Volume: 7 | Issue: 1 | Pages: 17

10.1001/jamacardio.2021.4567 | PMID 34730769 Get It

Three-dimensional microscale hanging drop arrays with geometric control for drug screening and live tissue imaging
Ganguli, Anurup , Mostafa, Ariana , Saavedra, Carlos , Kim, Yongdeok , Le, Phuong , Faramarzi, Vahid , Feathers, Ryan W. , Berger, Jacob , Ramos-Cruz, Karla P. , Adeniba, Olaoluwa O. , Diaz, Gustavo, Drnevich, Jenny , Wright, Chris , Hernandez, Alvaro G. , Lin, Wen-Wei , Smith, Andrew M. , Kosari, Farhad , Vasmatzis, George , Anastasiadis, Panos Z. , Ganguli, A , Mostafa, A , Le, P , Faramarzi, V , Ramos-Cruz, K P , Drnevich, J , Wright, Christy L , Hernandez, Alvaro G , Smith, A M , Anastasiadis, P Z , Bashir, R , Saavedra, C., Bashir, Rashid

Mayo Clinic

Science Advances | April 23, 2021 | Volume: 7 | Issue: 17 | Pages: No page available

10.1126/sciadv.abc1323 | PMID 33893093 Get It

Tiny silicon microchip–based high-throughput hanging drop arrays allow drug screening and geometric control.
Targeted Sequencing Reveals Novel Gene Mutations Associated with Transformation and Early Progression in Follicular Lymphoma
Kridel, Robert , Chan, Fong Chun , Boyle, Merrill, Farinha, Pedro , Tan, King, Meissner, Barbara , Bashashati, Ali , Giné, Eva , Ennishi, Daisuke , Mungall, Andrew J. , Johnson, Nathalie A. , Tousseyn, Thomas , Gascoyne, Randy D. , Farinha, Pedro , Mungall, Andrew J , Kridel, Robert , Mottok, Anja , Ben‐Neriah, Susana , Morin, Ryan D , Sehn, Laurie H. , Doǧan, Ahmet , Connors, Joseph M. , Scott, David W. , Steidl, Christian , Marra, Marco A. , Shah, Sohrab P.

Mayo Clinic

Blood | October 12, 2019 | Volume: 128 | Issue: 22 | Pages: 2919-2919

10.1182/blood.v128.22.2919.2919 Get It

Abstract Introduction : Follicular lymphoma (FL) remains an incurable malignancy as patients eventually experience progressive disease. A subset of patients is at risk of early lymphoma-related mortality due to histological transformation (TFL) to aggressive lymphoma (2-3% of patients per year) or early progression after immuno-chemotherapy, each of which leads to shortened survival. Mutations associated with transformation and/or early progression have been reported in the literature (e.g. CDKN2A, TP53, B2M) and the m7-FLIPI clinico-genetic risk model defines a high-risk patient group with poor failure-free survival after first-line treatment. However, the current knowledge of genetic alterations underlying transformation and/or early progression is inadequate to explain the majority of transformed cases and accurately predict early progressive disease. Materials and Methods: We performed targeted capture-based sequencing of 94 genes in a large cohort of fresh-frozen and formalin-fixed and paraffin-embedded patient specimens (402 samples in total). This cohort comprised 277 samples from 159 patients that experienced transformation (including 128 samples at T1 (the time of FL) and 149 samples at T2 (the time of transformation) with 118 paired biopsies) and 125 samples from 125 patients (pre-treatment samples only) presenting with either early progression within 2.5 years after starting immunochemotherapy (n=41) or late or never progression for at least 5 years after starting immunochemotherapy or observation (n=84). Mutations were called using MutationSeq and putative single nucleotide polymorphisms were filtered out using either matching germline samples (n=84) or dbSNP (v147). Bayesian proportion tests were used to compare the prevalence of gene mutations between groups. Results : We first compared T1 (n=128) and T2 (n=149) samples from 159 patients experiencing transformation. Eleven genes were more commonly altered in transformed lymphoma. These included genes that had previously been associated with transformation, such as TP53, B2M, MYC and EBF1, as well as genes that have not yet been implicated as contributing to this process, for example EZH2, CCND3, PIM1 and ITPKB. Moreover, mutations in GNA13, S1PR2 and P2RY8, that have been implicated in dissemination of germinal centre B cells, were enriched in T2 samples. In addition, cell-of-origin classification was available for 108 of the TFL cases with DLBCL histology, 18 and 90 of which were of the ABC and GCB subtype, respectively. Although the number of ABC-TFL cases was small, we observed higher percentages of BCL10 (16% versus 1%, Fisher P=0.004), CD79B (22% versus 4%, Fisher P=0.005) and MYD88 mutations (28% versus 9%, P=0.006) in ABC-TFL than in GCB-TFL, suggesting that B-cell receptor signaling and NF-κB signaling are important contributors to the ABC phenotype in TFL. Next, we assessed the association of gene mutations with patient outcomes contrasting early progressers (n=41) and late or non-progressers (n=84). Eleven genes were mutated more commonly in early progressers than in late progressers, including KMT2C, TP53, BTG1, MKI67, XBP1 and SOCS1. Overall, 32 out of 41 early progressers (78%) had mutations in at least one of the 11 early progression-associated genes, but none of the individual early progression-associated genes were mutated at a frequency > 22%. Thus, early progression appears to be related to relatively infrequent genetic alterations. None of the early progression-associated gene mutations form part of the m7-FLIPI outcome predictor. Furthermore, in our cohort that was enriched for clinical extremes, the m7-FLIPI was similarly associated with early progression when compared to the FLIPI but it was not superior, having higher specificity (89% versus 76%), but lower sensitivity (36% versus 63%). Conclusions: We found novel associations of gene mutations with transformation and showed that TFL is molecularly heterogeneous, with the ABC subtype being characterized by differential gene mutation when compared to the GCB subtype. With regards to progressive disease after immuno-chemotherapy, our approach identified early progression as a distinct clinico-genetic disease category that is imperfectly captured by traditional prognostic tools. Disclosures Connors: Seattle Genetics: Research Funding; Bristol Myers Squib: Research Funding; F Hoffmann-La Roche: Research Funding; NanoString Technologies: Research Funding; Millennium Takeda: Research Funding. Scott:NanoString Technologies: Patents & Royalties: named inventor on a patent for molecular subtyping of DLBCL that has been licensed to NanoString Technologies.
Digital-resolution detection of microRNA with single-base selectivity by photonic resonator absorption microscopy
Canady, Taylor D., Li, Nantao , Smith, Lucas D. , Lu, Yi , Smith, Andrew M. , Cunningham, Brian T. , Kohli, Manish , Smith, A M , Cunningham, Brian T

Mayo Clinic

Proceedings of the National Academy of Sciences | September 9, 2019 | Volume: 116 | Issue: 39 | Pages: 19362-19367

10.1073/pnas.1904770116 | PMID 31501320 Get It

Significance Highly selective and sensitive detection of microRNA is a key challenge in the development of liquid-biopsy approaches. Technologies that can achieve high diagnostic performance without the requirement of complicated processing steps or expensive equipment are necessary for broad use. With these features in mind, we demonstrate a digital-readout microRNA diagnostic that fundamentally relies on microRNA-activated nanoparticle-photonic crystal hybrid coupling. The hybrid formation allows for clear detection of single-particle binding events due to enhanced nanoparticle absorption at the binding location. Whereas the applied photonics lend the assay concentration sensitivity, we additionally demonstrate broad placement single-base mismatch selectivity and complex media detection by applying free-energy tuned toehold probes.
Risk Locus Identification Ties Alcohol Withdrawal Symptoms toSORCS2
Smith, Andrew H. , Ovesen, Peter Lund , Skeldal, Sune , Yeo, Seungeun , Jensen, Kevin P. , Olsen, Ditte , Diazgranados, Nancy , Zhao, Hongyu , Goldman, David , Glerup, Simon , Nykjær, Anders , Nykjaer, Anders, Farrer, Lindsay A. , Kranzler, Henry R. , Gelernter, Joel E.

Mayo Clinic

Alcoholism: Clinical and Experimental Research | September 25, 2018 | Volume: 42 | Issue: 12 | Pages: 2337-2348

10.1111/acer.13890 | PMID 30252935 Get It

BackgroundEfforts to promote the cessation of harmful alcohol use are hindered by the affective and physiological components of alcohol withdrawal (AW), which can include life‐threatening seizures. Although previous studies ofAWand relapse have highlighted the detrimental role of stress, little is known about genetic risk factors.MethodsWe conducted a genome‐wide association study ofAWsymptom count in uniformly assessed subjects with histories of seriousAW, followed by additional genotyping in independentAWsubjects.ResultsThe top association signal forAWseverity was in sortilin family neurotrophin receptor geneSORCS2on chromosome 4 (European American meta‐analysisn = 1,478,p = 4.3 × 10−9). There were no genome‐wide significant findings in African Americans (n = 1,231). Bioinformatic analyses were conducted using publicly available high‐throughput transcriptomic and epigenomic data sets, showing that in humansSORCS2is most highly expressed in the nervous system. The identifiedSORCS2risk haplotype is predicted to disrupt a stress hormone‐modulated regulatory element that has tissue‐specific activity in human hippocampus. We used human neural lineage cells to demonstrate in vitro a causal relationship between stress hormone levels andSORCS2expression, and show thatSORCS2levels in culture are increased upon ethanol exposure and withdrawal.ConclusionsTaken together, these findings indicate that the pathophysiology of withdrawal may involve the effects of stress hormones on neurotrophic factor signaling. Further investigation of these pathways could produce new approaches to managing the aversive consequences of abrupt alcohol cessation.
Expanding the Dynamic Range of Fluorescence Assays through Single-Molecule Counting and Intensity Calibration
Smith, Lucas D. , Smith, Andrew M. , Kohli, Manish , Smith, A M

Mayo Clinic

Journal of the American Chemical Society | September 14, 2018 | Volume: 140 | Issue: 42 | Pages: 13904-13912

10.1021/jacs.8b08879 | PMID 30215524 Get It

Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model
Levings, Rachael S. Watson, Broome, Ted A., Rice, Brett L., Gibbs, Eric P., Myara, David A., Hyddmark, E. Viktoria, Zarezadeh, Ali , Levings, Padraic P., Lu, Yuan , White, Margaret , Dacanay, E. Anthony, Foremny, Gregory B., Evans, Christopher H. , Morton, Alison J. , Winter, Mathew, Dark, Michael J. , Nickerson, David M., Colahan, Patrick T., Ghivizzani, Steven C. , Smith, Andrew D. , Nasri, Elham , Foremny, Gregory B.

Mayo Clinic

Human Gene Therapy Clinical Development | June 5, 2018 | Volume: 29 | Issue: 2 | Pages: 90-100

10.1089/humc.2017.142 | PMID 29869540 Get It